Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Cathay Industrial Halts Listing Process
by Jean-François Tremblay
August 15, 2011
| A version of this story appeared in
Volume 89, Issue 33
Cathay Industrial Biotech, a Chinese company that produces chemicals by fermentation, has dropped plans to list its stock in the U.S. by means of American Depositary Shares. HBM BioVentures, a Swiss private equity fund that invested $28 million in Cathay, says Cathay decided to halt the listing process because of poor conditions in global stock markets. In 2010, Cathay recorded a loss of $2 million on sales of $125 million. The company produces diacids by biocatalysis for clients including DuPont and AkzoNobel. It also makes biobutanol.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter